SynAct Pharma (DB:8F8) - Hisse Senedi Fiyatı, Haberler ve Analizler

8F8 Stoklara Genel Bakış

Klinik aşamada bir biyoteknoloji şirketi olan SynAct Pharma AB, İsveç'te enflamatuar hastalıkların tedavisi için ilaçlar araştırmakta ve geliştirmektedir. Daha fazla detay

8F8 temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( SEK0 )

Kazançlar son 5 yılda yılda 42.9% oranında azaldı

Son 3 ayda dalgalı hisse senedi fiyatı

Hissedarlar geçen yıl sulandırıldı

+ 1 daha fazla risk

SynAct Pharma AB Rakipler

4SC

DB:VSC

€50.2m

Medigene

XTRA:MDG1

€17.0m

2invest

XTRA:2INV

€64.4m

Heidelberg Pharma

XTRA:HPHA

€110.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti SynAct Pharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	SEK 0.95
52 Haftanın En Yüksek Seviyesi	SEK 1.13
52 Haftanın En Düşük Seviyesi	SEK 0.53
Beta	0.65
11 Aylık Değişim	25.79%
3 Aylık Değişim	26.29%
1 Yıllık Değişim	73.86%
33 Yıllık Değişim	-92.80%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-88.79%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	8F8	DE Biotechs	DE Pazar
7D	23.3%	1.1%	1.3%
1Y	73.9%	-18.5%	7.9%

Getiri vs. Endüstri: 8F8 geçen yıl % -18.5 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: 8F8 geçen yıl % 7.9 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is 8F8's price volatile compared to industry and market?
8F8 volatility
8F8 Average Weekly Movement	9.0%
Biotechs Industry Average Movement	6.7%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 8F8 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: 8F8 'nin haftalık oynaklığı son bir yılda 14% dan 9% a düştü, ancak hâlâ German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2012	5	Jeppe Ovlesen	synactpharma.com

Klinik aşamada bir biyoteknoloji şirketi olan SynAct Pharma AB, İsveç'te enflamatuar hastalıkların tedavisi için ilaçlar araştırmakta ve geliştirmektedir. Şirket, romatoid artrit, idiyopatik membranöz nefropati ve virüs kaynaklı solunum yetmezliği tedavisi için Faz 2 klinik çalışmasında bir ilaç adayı olan AP1189'u geliştirmektedir. Cerrahide organ yetmezliğinin önlenmesi için klinik öncesi çalışmalarda olan gelişmiş bir peptid agonisti olan TXP-11'i ve oto-immün ve enflamatuar hastalıkları tedavi etmek için çeşitli ilaç programları geliştirmektedir.

SynAct Pharma AB Temel Bilgiler Özeti

SynAct Pharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
8F8 temel i̇stati̇sti̇kler
Piyasa değeri	€40.66m
Kazançlar(TTM)	-€13.41m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-3.0x

F/K Oranı

8F8 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
8F8 gelir tablosu (TTM)
Gelir	SEK 0
Gelir Maliyeti	SEK 0
Brüt Kâr	SEK 0
Diğer Giderler	SEK 154.57m
Kazançlar	-SEK 154.57m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

Feb 18, 2025

Hisse başına kazanç (EPS)	-3.74
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

8F8 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

8F8 Stoklara Genel Bakış

Risk Analizi

SynAct Pharma AB Rakipler

DB:VSC

€50.2m

XTRA:MDG1

€17.0m

XTRA:2INV

€64.4m

XTRA:HPHA

€110.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

SynAct Pharma AB Receives EU Trial Approval for the Phase 2b Advance Study with Resomelagon (AP1189)

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 44.902176 million.

SynAct Pharma AB to Report Fiscal Year 2024 Results on Feb 18, 2025

SynAct Pharma AB Initiates the Phase 2b Advance Study with Resomelagon (AP1189) in the US

New major risk - Financial position

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon

Recent updates

SynAct Pharma AB Receives EU Trial Approval for the Phase 2b Advance Study with Resomelagon (AP1189)

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 44.902176 million.

SynAct Pharma AB to Report Fiscal Year 2024 Results on Feb 18, 2025

SynAct Pharma AB Initiates the Phase 2b Advance Study with Resomelagon (AP1189) in the US

New major risk - Financial position

SynAct Pharma AB Initiates Filing Process for Phase 2b Advance Study with Resomelagon

Chief Operating Officer recently bought €160k worth of stock

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 49.239162 million.

SynAct Pharma AB has filed a Follow-on Equity Offering in the amount of SEK 45 million.

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces CEO Changes

SynAct Pharma AB Announces Outcomes of the Independent Audit of the 4-Week Resolve P2a Clinical Trial in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces Resignation of Marina Bozilenko as Member of the Board of Directors

New major risk - Financial position

SynAct Pharma AB to Report Q3, 2024 Results on Oct 30, 2024

SynAct Pharma Announces Additional Data from the Expand P2b Clinical Trial Supporting Continued Development of the Compound in Rheumatoid Arthritis

SynAct Pharma AB to Report Q4, 2023 Results on Feb 23, 2024

High number of new and inexperienced directors

Synact Pharma Appoints Kristen Harting as Chief Medical Officer, Effective 15 February 2024

Synact Pharma Expands Its Rheumatology Clinical Advisory Board with Three New Highly Experienced Advisors

SynAct Pharma AB, Annual General Meeting, May 23, 2024

SynAct Pharma AB has completed a Follow-on Equity Offering in the amount of SEK 60.525 million.

SynAct Pharma AB Announces Evaluation of the 4-Week RESOLVE P2a Clinical Trial in Moderate to Severe Active Rheumatoid Arthritis Patients with an incomplete Response to Methotrexate

SynAct Pharma AB Announces Additional Data from the Expands P2b Clinical Trial Further Supporting Efficacy and Activity seen in Patients with Elevated CRP

SynAct Pharma AB Announces Additional Data from the EXPAND P2b Clinical Trial and Identifies Population with Responsiveness to Resomelagon

Synact Pharma Announces Top Line Data from the 12-Week Expand P2b Clinical Trial in Severe Active Newly Diagnosed Rheumatoid Arthritis Patients

SynAct Pharma AB (Publ) Completes Dosing in Part A of Combined Phase 2A/B Resomelagon (AP1189) in Rheumatoid Arthritis (RA)

SynAct Pharma AB (publ) Completes Patient Recruitment for Part A of Combined Phase 2a/b RESOLVE Study of Resomelagon (AP1189) in Rheumatoid Arthritis

SynAct Pharma AB (publ) Announces the Completion of Dosing in the Phase 2b Expand Study of Resomelagon (AP1189) in Early Severe Rheumatoid Arthritis Patients

SynAct Pharma AB Announces Appointment of Thomas Von Koch as Board Member

SynAct Pharma AB Appoints Björn Westberg as Chief Financial Officer

No independent directors

SynAct Pharma AB to Report Q1, 2023 Results on May 05, 2023

No independent directors

No independent directors

SynAct Pharma AB (OM:SYNACT) completed the acquisition of TXP Pharma AG from Boesen Biotech ApS, GL Capital AB, TJ Biotech Holding ApS, Quantass ApS, and James Knight.

SynAct Pharma AB Announces Change in Nomination Committee Prior to Agm 2023

Chief Operating Officer recently sold €317k worth of stock

SynAct Pharma AB (OM:SYNACT) entered into a conditional agreement to acquire TXP Pharma AG from Boesen Biotech Aps, Glcapital Ab, TJ Biotech Holding ApS, Quantass ApS, and James Knight for approximately SEK 190 million.

No independent directors

SynAct Pharma AB Receives IND Clearance from the FDA for Phase 2A/B Trial of Ap1189 in Ra

SynAct Pharma AB, Annual General Meeting, May 25, 2023

Synact Submits Ind and Recruits First Patient

Synact Pharma Submits IND for US Phase 2A/B Clinical Trial

SynAct Pharma AB (Publ) Enrolls First Patient in Phase 2b Trial of Ap1189 in RA

No independent directors

SynAct Pharma AB Announces Approval of Amended Study Protocol for the Phase 2A Study in iMN

SynAct Pharma AB (publ) Announces That the Clinical Trial Application to Initiate the Clinical Phase 2B Study, Expand

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

SynAct Pharma AB Improves the Design of the Ongoing Phase 2A Study in Imn

Synact Pharma Receives pre-IND Response from the U.S. Food and Drug Administration

SynAct Pharma Submits CTA for Clinical Phase 2b Study in RA

John Haurum Declines Re-Election as Board Member of SynAct Pharma AB

SynAct Pharma AB Completes Clinical Pharmacokinetic Test of Ap1189 Tablet

No independent directors

SynAct Pharma AB Announces Additional Data from the BEGIN Study

SynAct Pharma AB Reports Positive PK Data on AP1189 Tablets

SynAct Pharma AB Completes Patient Recruitment to the Phase 2A Begin Study of Ap1189 in Early Severe Rheumatoid Arthritis

SynAct Pharma AB Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis

SynAct Pharma AB Announces Grant of Key European Patent Covering Ap1189